Access to care along with a shortage of healthcare providers, especially psychiatric specialists is a widespread problem in many areas of Virginia. Patients who have 1 or more chronic illnesses frequently have coexisting psychiatric problems, and psychiatric patients often have at least 1 chronic health condition. To assist in addressing both behavioral health and primary care services for health promotion and disease prevention, a collaborative care model as outlined by the Substance Abuse and Mental Health Services Administration and the Health Resources and Services Administration was evaluated. The collaborative care model was compared with existing services and barriers to health care identified in a rural Virginia County. Identification and use of advanced practice nursing roles and improved collaboration among health care providers were emphasized. Evidence-based practice interventions and quality improvement strategies such as the plan-do-check-act model were identified and evaluated. Outcome measures outlining an evaluation plan for goals related to improving health outcomes were identified with recommendations for various accessible wellness programs.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1891/2380-9418.10.2.135 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Interim Analysis of a Prospective Polysomnographic Study of Weighted Blankets in Patients with Psychophysiological Insomnia.
Psychiatry Clin Psychopharmacol
December 2024
Sleep and Disorders Unit, Division of Clinical Neurophysiology, Department of Neurology, Cerrahpasa Faculty of Medicine, Istanbul University-Cerrahpasa, İstanbul, Türkiye.
Background: Weighted blankets have recently introduced in the treatment on insomnia as a nonpharmacological integrative therapy. Here we prospectively evaluated the effects of weighted blankets on the sleep structure and heart rate variability (HRV) in patients with primary psychophysiological insomnia.
Methods: In this prospective polysomnographic (PSG) study between August 2021 and August 2022, patients were given weighted blankets (~10% of body weight) to use at home for 10 nights consecutively.
Plasma Interleukin-35 Levels Predict the Prognosis in Patients with HBV-Related Acute-on-Chronic Liver Failure.
Viruses
December 2024
Department of Infection and Immunity, Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508, China.
This study aimed to investigate the impact of IL-35 on the prognosis of patients with HBV-ACLF. We recruited 69 patients with HBV-ACLF, 20 patients with chronic hepatitis B (CHB), 17 patients with liver cirrhosis (LC), and 20 healthy controls (HCs) from a regional infectious disease treatment center in China. Plasma levels of IL-35 at baseline were detected using ELISA.
View Article and Find Full Text PDFCharacterization of Hepatitis B Virus Transcripts in Chronically HBV-Infected Chimpanzees and Patients Treated with ARC-520 siRNA Demonstrates Transcriptional Silencing of cccDNA.
Viruses
December 2024
Department of Medicine & State Key Laboratory of Liver Research, School of Clinical Medicine, The University of Hong Kong, Hong Kong, China.
Full-length hepatitis B virus (HBV) transcripts of chimpanzees and patients treated with multidose (MD) HBV siRNA ARC-520 and entecavir (ETV) were characterized by single-molecule real-time (SMRT) sequencing, identifying multiple types of transcripts with the potential to encode HBx, HBsAg, HBeAg, core, and polymerase, as well as transcripts likely to be derived from dimers of dslDNA, and these differed between HBeAg-positive (HBeAg+) and HBeAg-negative (HBeAg-) individuals. HBV transcripts from the last follow-up ~30 months post-ARC-520 treatment were categorized from one HBeAg+ (one of two previously highly viremic patients that became HBeAg- upon treatment and had greatly reduced cccDNA products) and four HBeAg- patients. The previously HBeAg+ patient received a biopsy that revealed that he had 3.
View Article and Find Full Text PDFChronic Hepatitis C Infection Treated with Direct-Acting Antiviral Agents and Occurrence/Recurrence of Hepatocellular Carcinoma: Does It Still Matter?
Viruses
December 2024
Department of Translational Medicine, Università del Piemonte Orientale, 28100 Novara, Italy.
Hepatitis C virus (HCV) infection is a significant risk factor for liver cirrhosis and hepatocellular carcinoma (HCC). Traditionally, the primary prevention strategy for HCV-associated HCC has focused on removing infection through antiviral regimes. Currently, highly effective direct-acting antivirals (DAAs) offer extraordinary success across all patient categories, including cirrhotics.
View Article and Find Full Text PDFCase of Fatal Hepatitis Related to HEV-3 Infection in Central Italy.
Viruses
November 2024
Microbiology and Clinical Microbiology Section, Department of Medicine and Surgery, University of Perugia, 06132 Perugia, Italy.
Hepatitis E virus (HEV) is a global health problem, causing an estimated 20 million infections annually. Thus, the management of HEV requires special consideration. In developed countries, hepatitis E is mainly recognized as a foodborne disease (mainly transmitted via undercooked meat consumption) that is generally caused by genotype 3 and 4 circulating in various animals, including pigs and wild boars.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!